| Pembrolizumab in microsatellite-instability–high advanced colorectal cancer T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... New England Journal of Medicine 383 (23), 2207-2218, 2020 | 1879 | 2020 |
| High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study AL Appelt, J Pløen, H Harling, FS Jensen, LH Jensen, JCR Jørgensen, ... The lancet oncology 16 (8), 919-927, 2015 | 547 | 2015 |
| Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised … LA Diaz, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... The Lancet Oncology 23 (5), 659-670, 2022 | 349 | 2022 |
| Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. T Andre, KK Shiu, TW Kim, BV Jensen, LH Jensen, CJA Punt, DM Smith, ... Journal of Clinical Oncology 38 (18_suppl), LBA4-LBA4, 2020 | 243 | 2020 |
| Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma … A Stein, D Arnold, J Bridgewater, D Goldstein, LH Jensen, HJ Klümpen, ... BMC cancer 15, 1-8, 2015 | 226 | 2015 |
| Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab … T Andre, M Amonkar, JM Norquist, KK Shiu, TW Kim, BV Jensen, ... The Lancet Oncology 22 (5), 665-677, 2021 | 157 | 2021 |
| Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial A Jakobsen, F Andersen, A Fischer, LH Jensen, JCR Jørgensen, ... Acta Oncologica 54 (10), 1747-1753, 2015 | 114 | 2015 |
| Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer LH Jensen, J Lindebjerg, J Ploen, TF Hansen, A Jakobsen Annals of oncology 23 (9), 2341-2346, 2012 | 111 | 2012 |
| Prognostic factors for progression-free and overall survival in advanced biliary tract cancer J Bridgewater, A Lopes, H Wasan, D Malka, L Jensen, T Okusaka, J Knox, ... Annals of Oncology 27 (1), 134-140, 2016 | 97 | 2016 |
| Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic … T Andre, KK Shiu, TW Kim, BV Jensen, LH Jensen, CJA Punt, DM Smith, ... Journal of Clinical Oncology 39 (15_suppl), 3500-3500, 2021 | 73 | 2021 |
| Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC LH Jensen, K Osterlind, C Rytter Lung Cancer 62 (1), 85-91, 2008 | 71 | 2008 |
| KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. KK Shiu, T Andre, TW Kim, BV Jensen, LH Jensen, CJA Punt, DM Smith, ... Journal of Clinical Oncology 39 (3_suppl), 6-6, 2021 | 52 | 2021 |
| Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy TF Hansen, S Kjær-Frifeldt, J Lindebjerg, SR Rafaelsen, LH Jensen, ... Acta Oncologica 57 (4), 528-533, 2018 | 50 | 2018 |
| Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency LH Jensen, J Lindebjerg, L Byriel, S Kolvraa, DG Crüger Colorectal Disease 10 (5), 490-497, 2008 | 47 | 2008 |
| Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts TF Hansen, S Kjær-Frifeldt, AC Eriksen, J Lindebjerg, LH Jensen, ... British Journal of Cancer 119 (11), 1367-1373, 2018 | 41 | 2018 |
| An update on immune checkpoint therapy for the treatment of Lynch syndrome C Therkildsen, LH Jensen, M Rasmussen, I Bernstein Clinical and experimental gastroenterology, 181-197, 2021 | 40 | 2021 |
| Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer E Dizdarevic, TF Hansen, J Pløen, LH Jensen, J Lindebjerg, S Rafaelsen, ... International Journal of Radiation Oncology* Biology* Physics 106 (3), 556-563, 2020 | 39 | 2020 |
| EGF61A> G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer KLG Spindler, RF Andersen, LH Jensen, J Ploen, A Jakobsen Annals of oncology 21 (3), 535-539, 2010 | 37 | 2010 |
| Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma CB Thomsen, TF Hansen, RF Andersen, J Lindebjerg, LH Jensen, ... Journal of Experimental & Clinical Cancer Research 37, 1-7, 2018 | 36 | 2018 |
| Early, integrated palliative rehabilitation improves quality of life of patients with newly diagnosed advanced cancer: The Pal-Rehab randomized controlled trial L Nottelmann, M Groenvold, TB Vejlgaard, MA Petersen, LH Jensen Palliative medicine 35 (7), 1344-1355, 2021 | 35 | 2021 |
Søren R Rafaelsen, MD, DMScProfessor (Abdominal Radiology), University of Southern DenmarkVerified email at slb.regionsyddanmark.dk
